Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Highlights

Highlights July 2013 In This Issue Volume 131, Number 7 Pages 825 - 976 JAMA Ophthalmology Formerly Archives of Ophthalmology LEttERs Research Research Letter CLINICAL TRIAL 955 Oral Glucosamine Supplements as a Lutein/Zeaxanthin for the Treatment of Age-Related Cataract 843 Possible Ocular Hypertensive Agent RK Murphy and Coauthors Chew and colleagues evaluated lutein/zeaxanthin supplementation for the treatment of age- 957 Progression of Diabetic related cataract, a leading cause of blindness in the United States, with more than 30 million Retinopathy in the Hypertension individuals likely to be affected by 2020. In a randomized clinical trial of 3159 phakic partici- Intervention Nurse Telemedicine Study pants with varying degrees of age-related macular degeneration, there was no statistically KW Muir and Coauthors significant effect of supplementation of lutein/zeaxanthin, 10 mg/2 mg, for cataract surgery 958 Long-term Suppression of or the development of cortical and posterior subcapsular cataracts. For participants with the Multidrug-Resistant Cytomegalovirus Retinitis With Systemically lowest quintile of dietary intake of lutein/zeaxanthin, there was a beneficial effect. Administered Leflunomide CME jamanetworkcme.com JH Dunn and Coauthors 960 Sclerochoroidal Calcification Is CLINICAL SCIENCES Primarily a Scleral Condition Based Giant Conjunctival Nevus 857 on Enhanced Depth Imaging Optical A retrospective analysis of 32 cases of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Ophthalmology American Medical Association

Highlights

JAMA Ophthalmology , Volume 131 (7) – Jul 1, 2013

Highlights

Abstract

July 2013 In This Issue Volume 131, Number 7 Pages 825 - 976 JAMA Ophthalmology Formerly Archives of Ophthalmology LEttERs Research Research Letter CLINICAL TRIAL 955 Oral Glucosamine Supplements as a Lutein/Zeaxanthin for the Treatment of Age-Related Cataract 843 Possible Ocular Hypertensive Agent RK Murphy and Coauthors Chew and colleagues evaluated lutein/zeaxanthin supplementation for the treatment of age- 957 Progression of Diabetic related cataract, a leading cause of blindness in the...
Loading next page...
 
/lp/american-medical-association/highlights-laBMxhKtzh
Publisher
American Medical Association
Copyright
Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6165
eISSN
2168-6173
DOI
10.1001/jamaophthalmol.2013.4121
Publisher site
See Article on Publisher Site

Abstract

July 2013 In This Issue Volume 131, Number 7 Pages 825 - 976 JAMA Ophthalmology Formerly Archives of Ophthalmology LEttERs Research Research Letter CLINICAL TRIAL 955 Oral Glucosamine Supplements as a Lutein/Zeaxanthin for the Treatment of Age-Related Cataract 843 Possible Ocular Hypertensive Agent RK Murphy and Coauthors Chew and colleagues evaluated lutein/zeaxanthin supplementation for the treatment of age- 957 Progression of Diabetic related cataract, a leading cause of blindness in the United States, with more than 30 million Retinopathy in the Hypertension individuals likely to be affected by 2020. In a randomized clinical trial of 3159 phakic partici- Intervention Nurse Telemedicine Study pants with varying degrees of age-related macular degeneration, there was no statistically KW Muir and Coauthors significant effect of supplementation of lutein/zeaxanthin, 10 mg/2 mg, for cataract surgery 958 Long-term Suppression of or the development of cortical and posterior subcapsular cataracts. For participants with the Multidrug-Resistant Cytomegalovirus Retinitis With Systemically lowest quintile of dietary intake of lutein/zeaxanthin, there was a beneficial effect. Administered Leflunomide CME jamanetworkcme.com JH Dunn and Coauthors 960 Sclerochoroidal Calcification Is CLINICAL SCIENCES Primarily a Scleral Condition Based Giant Conjunctival Nevus 857 on Enhanced Depth Imaging Optical A retrospective analysis of 32 cases of

Journal

JAMA OphthalmologyAmerican Medical Association

Published: Jul 1, 2013

There are no references for this article.